Jami Rubin, the pharmaceuticals analyst at Morgan Stanley, points to Merck's healthy balance sheet.

FORBES: Magazine Article

Goldman Sachs analyst Jami Rubin has been pushing a breakup for years.

FORBES: Will Pfizer Break Up?

No, says Jami Rubin at Goldman Sachs, who was one of the first analysts to start pushing for a Pfizer breakup in 2008.

FORBES: Pfizer Spinoffs May Be Prelude To A Bigger Breakup, Analyst Says

Jami Rubin, the pharmaceuticals analyst at Morgan Stanley (nyse: MS - news - people ), points to Merck's healthy balance sheet.

FORBES: Forget Vioxx?

On the company's conference call, Jami Rubin at Morgan Stanley complained that Schering's guidance on Vytorin and Zetia sales amounts basically to saying they will go down.

FORBES: Magazine Article

Jami Rubin, a pharmaceuticals analyst with Morgan Stanley, believes New Jersey Superior Court Judge Carol Higbee has tried, through her actions and rulings, to dissuade Merck from pursuing a long and drawn out legal fight.

FORBES: A Hopeful Sign For Merck

Many analysts, including Jami Rubin at Goldman Sachs and, more recently, Timothy Anderson at Bernstein Research, have argued that Pfizer could split up the company in such a way that the remaining drug division could be a small, fast-growing pharma.

FORBES: Pfizer Decides Against Radical Surgery